Bimagrumab Results Timeline: What Studies Measured, and When

Answer first: the timeline in published trials was set by study visits, not by symptoms

Bimagrumab is an investigational human monoclonal antibody directed against activin type II receptors, and a 2024 review described it as an agent under investigation for obesity rather than an approved medicine (PMID 39385353). Because it was studied as an intravenous antibody given at multi-week intervals, the "timeline" in the literature is a schedule of protocol-defined assessment visits. The phase 2 trial in adults with type 2 diabetes and obesity administered bimagrumab 10 mg/kg (up to 1,200 mg) intravenously every 4 weeks for 48 weeks and measured fat mass and lean mass using dual-energy x-ray absorptiometry (PMID 33439265). Readers looking for a moment when "results appear" will not find one named in these publications; what exists is a set of measured endpoints at defined weeks.

What was measured, and when: a study-by-study map

48 weeks: the obesity and type 2 diabetes trial

The most frequently referenced body-composition dataset comes from a phase 2 randomised clinical trial in adults with type 2 diabetes and obesity, in which bimagrumab 10 mg/kg (capped at 1,200 mg) was infused every 4 weeks for 48 weeks alongside diet and exercise counselling in both arms (PMID 33439265). The study's primary measure was change in total body fat mass from baseline to week 48, and researchers reported a substantially larger reduction in fat mass with bimagrumab than with placebo, together with an increase in lean mass and a reduction in HbA1c (PMID 33439265).

Two points about timing matter when reading that trial. First, the endpoint was anchored at 48 weeks, so the publication describes a year-long comparison rather than a week-by-week curve. Second, the comparison was against placebo within a trial population selected for type 2 diabetes and obesity, which is not the same as a general statement about any individual. A 2022 pharmacology review of drugs for treating obesity placed agents of this kind in the broader context of investigational and approved weight-management pharmacotherapy (PMID 34783910).

24 weeks: sarcopenia in older adults

A separate randomised clinical trial compared bimagrumab with optimised standard of care, nutrition and a home-based exercise programme, in community-dwelling older adults with sarcopenia, using monthly intravenous infusions across a 24-week treatment period (PMID 33074327). The primary endpoint was a functional one, the Short Physical Performance Battery, assessed after the treatment period, and researchers reported that bimagrumab did not produce a significant advantage over optimised standard of care on that functional measure despite measurable changes in body composition (PMID 33074327).

That dissociation, measurable tissue change without a matching change on the chosen functional scale within the trial's timeframe, is one of the most instructive findings in the bimagrumab literature for anyone thinking about timelines. A 2025 review of therapeutic advances in sarcopenia management discussed pharmacological approaches alongside established exercise and nutrition interventions and the difficulty of translating anabolic signals into functional endpoints (PMID 40580805).

52 weeks and beyond: sporadic inclusion body myositis

Sporadic inclusion body myositis is described in the rheumatology literature as a slowly progressive inflammatory myopathy affecting older adults, with limited treatment options (PMID 25215417). Bimagrumab was tested in this population in the RESILIENT programme, and the published long-term extension reported efficacy and safety outcomes in participants who continued treatment beyond the core randomised period, with 6-minute walking distance among the measures of interest (PMID 33597289). This dataset is notable because it extends observation well past a year, which is longer than most body-composition work on the molecule.

Combination with a GLP-1 receptor agonist: what the randomised and animal work measured

A randomised phase 2 trial published in 2026 evaluated bimagrumab plus semaglutide, each alone and in combination, for the treatment of obesity, and reported body-composition and weight outcomes across the randomised treatment arms (PMID 41772149). That design is directly relevant to the timeline question, because it compares what happens to lean and fat compartments under an incretin agent alone against what happens when activin receptor blockade is added.

Preceding that human work, a 2024 animal study, explicitly preclinical, not human, reported that antibody blockade of activin type II receptors preserved skeletal muscle mass and enhanced fat loss during GLP-1 receptor agonism in rodents (PMID 38218536). Rodent timelines do not translate to human weeks, and the paper should be read as mechanistic support rather than as a schedule for people.

Pharmacokinetics: why the dosing interval looked the way it did

A 2023 analysis of the pharmacokinetics and pharmacodynamics of bimagrumab (BYM338) characterised intravenous exposure and the relationship between drug exposure and pharmacodynamic changes, including lean body mass, across the clinical programme (PMID 36527600). Monoclonal antibodies are cleared slowly compared with small molecules, which is why trials used intervals measured in weeks rather than days; the phase 2 obesity and diabetes trial, for example, used a 4-weekly infusion schedule over 48 weeks (PMID 33439265). Exposure data describe how much drug is present over time; they do not establish when any individual would register a change.

What pooled analyses reported across trials

A 2024 systematic review and meta-analysis of bimagrumab's effect on body composition pooled randomised evidence and reported a consistent direction of change, increased lean mass and decreased fat mass, across the trials it included (PMID 39251484). A roll-up of that kind summarises endpoints already fixed by the individual protocols, so it inherits their timepoints: largely 24 weeks in sarcopenia (PMID 33074327) and 48 weeks in the metabolic setting (PMID 33439265). It does not create earlier data points that were never collected.

Adverse Events: What Studies Report

The phase 2 trial in adults with type 2 diabetes and obesity reported that mild diarrhoea and muscle spasms occurred more often with bimagrumab than with placebo over the 48-week treatment period (PMID 33439265). In the sarcopenia trial, researchers reported safety and tolerability alongside the functional and body-composition endpoints across 24 weeks of monthly infusions (PMID 33074327). The long-term extension of RESILIENT in sporadic inclusion body myositis contributed safety data over a longer exposure period than the other published trials (PMID 33597289). A 2024 review of bimagrumab as an investigational antibody for obesity summarised the tolerability picture reported to date (PMID 39385353).

Why a precise "time to results" cannot be read off this literature

• Endpoints were scheduled, not continuous. The obesity and diabetes trial anchored its primary body-composition endpoint at week 48 (PMID 33439265), and the sarcopenia trial anchored its primary functional endpoint after 24 weeks (PMID 33074327).
• Populations differed sharply. Older adults with sarcopenia (PMID 33074327), adults with type 2 diabetes and obesity (PMID 33439265) and adults with sporadic inclusion body myositis (PMID 33597289) are not interchangeable groups.
• Tissue change and function change were not the same endpoint. Researchers reported body-composition shifts without a corresponding primary functional benefit in the sarcopenia setting (PMID 33074327).
• Some supporting data are animal data. The muscle-preservation-during-GLP-1 finding was generated in rodents (PMID 38218536).
• Status is investigational. A 2024 review described bimagrumab as an investigational human monoclonal antibody, not an approved therapy (PMID 39385353).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition, medication or investigational agent. Nothing here describes a protocol, and no outcome described in these trials should be read as an expected result for any individual.

References

• Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial (JAMA Network Open, 2021)
• Bimagrumab vs Optimized Standard of Care for Treatment of Sarcopenia in Community-Dwelling Older Adults: A Randomized Clinical Trial (JAMA Network Open, 2020)
• Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT (Neurology, 2021)
• Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial (Nature Medicine, 2026)
• Effect of Bimagrumab on body composition: a systematic review and meta-analysis (Aging Clinical and Experimental Research, 2024)
• Pharmacokinetics and Pharmacodynamics of Bimagrumab (BYM338) (Clinical Pharmacokinetics, 2023)
• Bimagrumab: an investigational human monoclonal antibody against activin type II receptors for treating obesity (Journal of Basic and Clinical Physiology and Pharmacology, 2024)
• Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism (Molecular Metabolism, 2024)
• Therapeutic advances in sarcopenia management: From traditional interventions to personalized medicine (Clinical Nutrition, 2025)
• Drugs for Treating Obesity (Handbook of Experimental Pharmacology, 2022)
• Inclusion body myositis: update (Current Opinion in Rheumatology, 2014)